Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claims correctly reflect FDA label warnings that GAZYVA can cause HBV reactivation and PML, including death/fatal outcomes, and are consistent with the boxed warning and Warnings/Precautions sections provided.
Category Scores
Accurate Statements
GAZYVA can cause HBV reactivation and/or PML (progressive multifocal leukoencephalopathy), including potentially fatal outcomes.
Supported by boxed warning and Warnings/Precautions: HBV reactivation can result in fulminant hepatitis, hepatic failure, and death (5.1 and boxed warning); PML can be fatal (5.2 and boxed warning).
Obinutuzumab is marketed under the brand name Gazyva.
Supported implicitly by the provided label context identifying GAZYVA (obinutuzumab).
Unsupported Statements
Obinutuzumab is made by Roche/Genentech.
The provided prescribing information excerpts do not support manufacturer/origin claims.
In many markets, obinutuzumab is sold as Gazyva.
No label excerpt provided addresses country/market distribution or naming across markets.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only evaluated safety-related claim aligns with label language describing HBV reactivation and PML, including death/fatal outcomes.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two non-safety factual claims (manufacturer/origin; market-by-market naming) are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to label-supported information (e.g., boxed warning/Warnings/Precautions language for HBV reactivation and PML) and avoid manufacturer/market-distribution statements unless supported by label text.